Drugs in early clinical development for Systemic Lupus Erythematosus

Mariana Postal, Nailú Angélica Sinicato, Simone Appenzeller, Timothy B. Niewold

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.

Original languageEnglish (US)
Pages (from-to)573-583
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number5
DOIs
StatePublished - May 3 2016

Fingerprint

Systemic Lupus Erythematosus
Pharmaceutical Preparations
Therapeutics
Immunosuppressive Agents
Immune Tolerance
Toll-Like Receptors
Drug Design
Expert Testimony
B-Lymphocytes
Phosphotransferases
Down-Regulation
Clinical Trials
Cytokines
T-Lymphocytes
Peptides

Keywords

  • b cell
  • cytokine
  • Systemic lupus erythematosus
  • t cell

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Drugs in early clinical development for Systemic Lupus Erythematosus. / Postal, Mariana; Sinicato, Nailú Angélica; Appenzeller, Simone; Niewold, Timothy B.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 5, 03.05.2016, p. 573-583.

Research output: Contribution to journalArticle

Postal, Mariana ; Sinicato, Nailú Angélica ; Appenzeller, Simone ; Niewold, Timothy B. / Drugs in early clinical development for Systemic Lupus Erythematosus. In: Expert Opinion on Investigational Drugs. 2016 ; Vol. 25, No. 5. pp. 573-583.
@article{868277fb7ab14f0d852f7a737da4ecc5,
title = "Drugs in early clinical development for Systemic Lupus Erythematosus",
abstract = "Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.",
keywords = "b cell, cytokine, Systemic lupus erythematosus, t cell",
author = "Mariana Postal and Sinicato, {Nail{\'u} Ang{\'e}lica} and Simone Appenzeller and Niewold, {Timothy B.}",
year = "2016",
month = "5",
day = "3",
doi = "10.1517/13543784.2016.1162291",
language = "English (US)",
volume = "25",
pages = "573--583",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Drugs in early clinical development for Systemic Lupus Erythematosus

AU - Postal, Mariana

AU - Sinicato, Nailú Angélica

AU - Appenzeller, Simone

AU - Niewold, Timothy B.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.

AB - Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.

KW - b cell

KW - cytokine

KW - Systemic lupus erythematosus

KW - t cell

UR - http://www.scopus.com/inward/record.url?scp=84964040067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964040067&partnerID=8YFLogxK

U2 - 10.1517/13543784.2016.1162291

DO - 10.1517/13543784.2016.1162291

M3 - Article

C2 - 26950689

AN - SCOPUS:84964040067

VL - 25

SP - 573

EP - 583

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -